Figure 2 from Anti-HDGF Antibody Targets EGFR Tyrosine Kinase Inhibitor–Tolerant Cells in NSCLC Patient-Derived Xenografts

Anti-HDGF antibody enhances the efficacy of EGFR-targeted therapy. Mice with established PDXs of NSCLC tumors were randomized into two arms (n = 6 each) to receive osimertinib or osimertinib plus anti-HDGF antibody. A and B, Spider plot of tumor volume changes in mice treated with osimertinib or osimertinib plus anti-HDGF antibody. C and D, Waterfall plot of best percent change from baseline of each tumor in the two treatment arms. E and F, Mean percent change from baseline in the two treatment arms. Asterisks mark the data point in which there is a significant difference between the two treatment arms. G and H, Kaplan–Meier plot of PFS of mice in the two treatment arms. Graphs show the results of TM00219 (A, C, E, and G) and TM00199 (B, D, F, and H).